Prescrire's Médicaments en Questions: First results of a practice improvement programme [0.03%]
循证药物评价与用药建议：实践改进项目初步结果
In 2014, Prescrire launched a new distance-learning practice improve- ment programme for subscribers to our French edition, called M6dicaments en Questions (Medicines in Question).The aim of this programme is to help healthcare professional...
Resectable non-small cell lung cancer Adjuvant chemotherapy: slightly longer survival [0.03%]
可切除的小细胞肺癌 术后的化疗：略延长生存期
About one-quarter of cases of non- small cell lung cancer are diagnosed sufficiently early, i.e. at stages I to lIlA, to envisage surgical resection. Despite this surgery, the prognosis remains poor. In 2016, what is the harm-benefit balanc...
Diethylstilbestrol(DES) is a synthet- ic nonsteroidal oestrogen and endo- crine disruptor that was used in the 1950s-1970s to prevent spontaneous abortion, despite its lack of proven efficacy. Millions of women worldwide took DES during pre...
Nivolumab (OPDIVOO) BRAF V600 mutation-negative metastatic or inoperable melanoma: survival advantage [0.03%]
尼伏单抗(BRAF V600阴性转移或不可手术黑色素瘤：生存优势
Existing drugs are poorly effective in patients with inoperable or meta- static melanoma without a mutation in the BRAF gene at position V600. The first-line treatment of choice for patients with BRAF V600-positive melanoma is a combination...
Trametinib (MEKINIST°) Metastatic or inoperable BRAF V600-positive melanoma: a few extra months of life [0.03%]
曲美替尼（Mekinist）治疗BRAF V600突变阳性黑色素瘤：多活几个月
About 50% of patients with meta- static or inoperable melanoma carry a tumour with BRAF V600 mutation.The drug of first choice for these patients is vemurafenib, a BRAF inhibitor, which appears to prolong survival by a few months. Dabrafeni...
The system in operation since the late 20th cen- tury for stimulating pharmaceutical research and development (R&D) is increasingly showing seri- ous limitations. In particular, the new drugs it pro- duces are unaffordable and often offer o...